These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 11758555)

  • 1. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
    Binder GM
    Curr Opin Biotechnol; 1999 Jun; 10(3):303-6. PubMed ID: 10361077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congress passes FDA reform act: nuclear medicine community stands to gain.
    Kotz D
    J Nucl Med; 1998 Jan; 39(1):15N-16N, 18N. PubMed ID: 9443722
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 7. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 8. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA: friend or foe?
    Lewis TS
    Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear medicine wins decision in FDA PET case.
    Nichols D
    J Nucl Med; 1997 Dec; 38(12):23N. PubMed ID: 9430453
    [No Abstract]   [Full Text] [Related]  

  • 11. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA plan for statutory compliance. Notice of availability.
    Fed Regist; 1998 Nov; 63(226):65000-40. PubMed ID: 10338873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will politics sidetrack FDA reform?
    Gatty B
    Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract]   [Full Text] [Related]  

  • 16. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA: a dromedary tale.
    Nat Biotechnol; 1997 Jan; 15(1):1. PubMed ID: 9035089
    [No Abstract]   [Full Text] [Related]  

  • 19. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.